返回
Adaptimmune Therapeutics PLC（ADAP）價格
ADAP 股價走勢圖
ADAP 收益
Adaptimmune Therapeutics PLC
$0.04
-3%
$0
截至今日：Jan 22, 14:14:24 GMT-5
最新獲利結果： Q2 '25
報導： 2025-08-13
歷史收益
每季
年度
EPS
收入
Earnings FAQ
ADAP 最近的每股盈餘與預期相比如何？
Adaptimmune Therapeutics PLC ADAP 上一季度的收入表現如何？
Adaptimmune Therapeutics PLC 的收入預期是多少？
Adaptimmune Therapeutics PLC 的盈利品質評分是多少？
Adaptimmune Therapeutics PLC 何時發布財報？
Adaptimmune Therapeutics PLC 的預期收益是多少？
Adaptimmune Therapeutics PLC 是否超出收益預期？
關鍵數據
前收市價
$0.05
開盤價
$0.0425
當日範圍
$0.0425 - $0.0599
52週區間
$0.0202 - $0.685
交易量
1.6M
平均成交量
72.5M
每股盈餘 (TTM)
-0.11
股息收益率
--
市值
$12.8M
什麼是 ADAP？
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. The company is headquartered in Abingdon, Oxfordshire and currently employs 506 full-time employees. The company went IPO on 2015-05-06. PRAME is highly expressed across a range of solid tumors, including ovarian, endometrial, lung and breast cancers. The CD70 program targets the CD70 antigen, which is expressed across a range of hematological malignancies (acute myeloid leukemia and lymphoma) and solid tumors (renal cell carcinoma). The company is using TRuC technology to develop a T-cell therapy (ADP-520) against CD70, with membrane bound IL-15 to enhance persistence. ADP-520 is in pre-clinical testing. TRuC technology combines the targeting of CAR-T cells with T-cell TCR signaling.